Polynovo Limited PNV
ASX · Avustralya · Sağlık Teknolojisi
AUD 0,9000-0,03 (-%2,70)
Piyasa kapalı· · AUD · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Piyasa kapalı· · AUD · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
PolyNovo CEO Bruce Peatey talked with Proactive at the ASX Small and Mid-Cap Conference about its proprietary NovoSorb® polymer, the performance of the company, addressable market and what’s next for the company. PolyNovo (ASX: PNV) is a leading medical technology company transforming the management of complex wounds. Headquartered in Melbourne, Australia, it has international operations in the United States, United Kingdom, India, Hong Kong and Singapore and several other markets supported by distributor partners. The proprietary NovoSorb® polymer is addressing significant unmet needs in woun
The Australian market is experiencing a potential rebound, buoyed by positive developments on Wall Street and a decline in Brent crude prices. As investors navigate these shifting conditions, the appeal of penny stocks remains noteworthy for those seeking opportunities in smaller or newer companies. While the term "penny stocks" may seem outdated, these investments can still offer surprising value by focusing on companies with robust financials and clear growth trajectories.
As the Australian share market faces a challenging period with consecutive days of declines, investors are keenly observing how global economic pressures and fluctuating commodity prices impact local indices. In this environment, growth companies with high insider ownership can be particularly appealing as they often demonstrate strong alignment between management and shareholder interests, making them potential standouts in a volatile market.
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.